These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23163560)

  • 1. Commentary: risk factors for gastrointestinal bleeding in NSAID users.
    Hawkey CJ
    Aliment Pharmacol Ther; 2012 Nov; 36(9):904; discussion 905. PubMed ID: 23163560
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR).
    Lanas A; Goldstein JL; Chan FK; Wilcox CM; Peura DA; Li C; Sands GH; Scheiman JM
    Aliment Pharmacol Ther; 2012 Sep; 36(5):485-92. PubMed ID: 22804104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
    Chan FK; Lanas A; Scheiman J; Berger MF; Nguyen H; Goldstein JL
    Lancet; 2010 Jul; 376(9736):173-9. PubMed ID: 20638563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit versus risk in the use of non-selective NSAIDs and selective COX-2 inhibitors.
    Aalbers J
    Cardiovasc J Afr; 2012 Jul; 23(6):356. PubMed ID: 23091830
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial.
    Chan FK; Wong VW; Suen BY; Wu JC; Ching JY; Hung LC; Hui AJ; Leung VK; Lee VW; Lai LH; Wong GL; Chow DK; To KF; Leung WK; Chiu PW; Lee YT; Lau JY; Chan HL; Ng EK; Sung JJ
    Lancet; 2007 May; 369(9573):1621-6. PubMed ID: 17499604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclooxygenase inhibitors and cardiovascular risk.
    Andersohn F; Suissa S; Garbe E
    JAMA; 2007 Feb; 297(6):586-7; author reply 587-8. PubMed ID: 17299191
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan.
    Sakamoto C; Soen S
    Digestion; 2011; 83(1-2):108-23. PubMed ID: 21042022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis.
    Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands.
    Al MJ; Maniadakis N; Grijseels EW; Janssen M
    Value Health; 2008; 11(4):589-99. PubMed ID: 18194404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are COX-2 inhibitors safe for anyone.
    Bloomfeld RS
    Inflamm Bowel Dis; 2006 Sep; 12(9):922-3. PubMed ID: 16954813
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
    Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
    J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COX-2 inhibitors in patients with sensitivity to nonselective NSAIDs.
    Cimbollek S; Quiralte J; Avila R
    N Engl J Med; 2009 Nov; 361(22):2197-8. PubMed ID: 19940308
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cardiovascular risk of non-steroidal anti-inflammatory drugs].
    Hermann M
    Praxis (Bern 1994); 2012 Oct; 101(20):1309-14. PubMed ID: 23032496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients.
    Lee YC; Chang CH; Lin JW; Chen HC; Lin MS; Lai MS
    Liver Int; 2012 May; 32(5):859-66. PubMed ID: 22226322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors.
    Lai SW; Liao KF
    J Gastroenterol; 2013 May; 48(5):674. PubMed ID: 23508262
    [No Abstract]   [Full Text] [Related]  

  • 16. Celecoxib.
    Cheung R; Lowry S
    J R Soc Med; 2006 Jul; 99(7):336. PubMed ID: 16816261
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
    Bingham CO; Sebba AI; Rubin BR; Ruoff GE; Kremer J; Bird S; Smugar SS; Fitzgerald BJ; O'Brien K; Tershakovec AM
    Rheumatology (Oxford); 2007 Mar; 46(3):496-507. PubMed ID: 16936327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease.
    Korzenik JR; Podolsky DK
    Clin Gastroenterol Hepatol; 2006 Feb; 4(2):157-9. PubMed ID: 16469674
    [No Abstract]   [Full Text] [Related]  

  • 19. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
    Patterson MK; Castellsague J; Walker AM
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):982-8. PubMed ID: 18711705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.